Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT02772211

Organisation Name: Sheba Medical Center

Overal Status: Unknown status

Start Date: June 2016

Last Update: May 13, 2016

Lead Sponsor: Sheba Medical Center

Brief Summary: This is a two-stage experiment; the first stage is an open label trial in which participants receive six intravenous (IV) treatments of ketamine. The second stage includes participants that responded to ketamine (i.e. reduction of 25% in their symptoms of depression, as measured by the Montgomery Asberg Depression Scale MADRS). The second stage is a double-blind, controlled clinical trial of D-cycloserine (DCS) vs. placebo, as maintenance treatment in patients who responded to ketamine treatment. The aim of the study is to determine whether 8 weeks of DCS maintenance therapy will prevent relapse of depressive symptoms following ketamine infusions

Conditions:
  • Treatment Resistant Depression


Total execution time in seconds: 0.17210984230042